Martínez SLM, Gálvez CKM, Pamplona SAP, Thowinson HMC, Hernández MA, Cuartas AYS, Mercado AG

Language: Spanish
References: 18
Page: 101-105
PDF size: 167.71 Kb.

ABSTRACT

Objective. To determine the clinical and epidemiological characteristics of adult patients with hematological malignancies under treatment with chemotherapy who develop febrile neutropenia.
Methodology. Retrospective descriptive observational study, which included patients with hematological malignancies under treatment with chemotherapy who presented febrile neutropenia treated in a high complexity hospital in the city of Medellin between January and December 2018 who met the following eligibility criteria: older than 18 years old, on chemotherapy with febrile neutropenia. Non-probability sampling of consecutive cases. The information was obtained through the review of medical records. The analysis was done in Microsoft Excel, the variables were calculated absolute and relative frequencies with percentages and proportions.
Results. 65 patients were included, of which 54% (35) were female, with a median age of 52 years. Regarding the diagnosis, acute lymphoblastic leukemia and chronic myeloid leukemia both predominated with 34% (22). All the patients received antibiotic therapy during their hospital stay, being the most used piperacillin/tazobactam with 63% (41). Regarding the cultures, 31% (20) had a positive blood culture, 11% (7) had a positive urine culture, they are not exclusive. Regarding the neutrophil count, the median was 0. 12% (8) of the patients died.
Conclusion. Febrile neutropenia is a frequent complication of chemotherapy in patients with hematological malignancies who, despite having high mortality, should always receive antibiotic treatment.

REFERENCES

1. Scrihuela-Vidal, F., Laporte, J., Albasanz-Puig, A. y Gudiol,C., “Update on the management of febrile neutropeniain hematologic patients”, Rev Esp Quimioter, 2019, 32 (2): 55-58.

2. Freifeld, A., Bow, E., Sepkowitz, K., Boeckh, M., Ito, J.,Mullen, C. et al., “Clinical practice guideline for the useof antimicrobial agents in neutropenic patients withcancer: 2010 update by the infectious diseases societyof America”, Clin Infect Dis, 2011, 52 (4): e56-93. doi:10.1093/cid/cir073.

3. Lewis, M.A., Hendrickson, A.W. y Moynihan, T.J., “Oncologicemergencies: pathophysiology, presentation,diagnosis, and treatment”, CA Cancer J Clin, 2011, 61(5): 287-314. doi: 10.3322/caac.20124.

4. Ferreira, J.N., Correia, B.R., Oliveira, R.M., Watanabe,S.N., Possari, J.F. y Lima, A.F.C., “Managing febrile neutropeniain adult cancer patients: an integrative reviewof the literature”, Rev Bras Enferm, 2017, 70 (6): 1301-1308. doi: 10.1590/0034-7167-2016-0247.

5. Al-Tawfiq, J., Hinedi, K., Khairallah, H., Saadeh, B., Abbasi,S., Noureen, M. et al., “Epidemiology and source ofinfection in patients with febrile neutropenia: a ten-yearlongitudinal study”, J Infect Public Health, 2019, 12 (3):364-366. doi: 10.1016/j.jiph.2018.12.006.

6. Rodríguez, M., Paneque, M. y González, J., “Importanciadel mapa microbiológico en el tratamiento antibióticoempírico de pacientes hematológicos con neutropeniafebril”, Rev Cubana Hematol Inmunol Hemoter, 2021,37 (2).

7. Higdon, M.L., Atkinson, C.J. y Lawrence, K.V., “Oncologicemergencies: recognition and initial management”,Am Fam Physician, 2018, 97 (11): 741-748.

8. Mhaskar, R., Clark, O.A., Lyman, G., Engel Ayer Botrel,T., Morganti Paladini, L. et al., “Colony-stimulating factorsfor chemotherapy-induced febrile neutropenia”,Cochrane Database Syst Rev, 2014, (10): cd003039. doi:10.1002/14651858.CD003039.pub2.

9. De Naurois, J., Novitzky-Basso, I., Gill, M.J., Marti,F.M., Cullen, M.H. y Roila, F., “esmo Guidelines WorkingGroup. Management of febrile neutropenia: esmo ClinicalPractice Guidelines”, Ann Oncol, 2010, 21 Suppl 5:v252-2566. doi: 10.1093/annonc/mdq196.

10. Hansen, B., Wendelbo, Ø., Bruserud, Ø., Hemsing, A.,Mosevoll, K. y Reikvam, H., “Febrile neutropenia in acuteleukemia. epidemiology, etiology, pathophysiologyand treatment”, Mediterr J Hematol Infect Dis, 2020, 12(1): e2020009. doi: 10.4084/MJHID.2020.009.

11. Fietz, T., Lück, A., Schulz, H., Harde, J., Losem, C., Grebhardt,S. et al., “Prophylaxis of chemotherapy-inducedneutropenia and febrile neutropenia with lipegfilgrastimin 2489 cancer patients: final results from the non-interventionalstudy nadir”, Curr Med Res Opin, 2019, 35 (7):1127-1138. doi: 10.1080/03007995.2018.1560200.

12. Gudiol, C., Aguilar-Guisado, M., Azanza, J., Candel, F.,Cantón, R., Carratalà, J. et al., “Executive summary ofthe consensus document of the Spanish Society ofInfectious Diseases and Clinical Microbiology (seimc),the Spanish Network for Research in Infectious Diseases(reipi) and the Spanish Society of Haematology andHaemotherapy (sehh) on the management of febrile neutropeniain patients with hematological malignancies”,Enferm Infecc Microbiol Clin, 2020, 38 (4): 174-181. doi:10.1016/j.eimc.2019.01.013.

13. Ghosh, I., Raina, V., Kumar, L., Sharma, A., Bakhshi, S. etal., “Profile of infections and outcome in high-risk febrileneutropenia: experience from a tertiary care cancercenter in India”, Med Oncol, 2012, 29 (2): 1354-1360.doi: 10.1007/s12032-011-9858-3.

14. Cataño, D., Marín, D., Rivera, J., Martínez, J., Sánchez,J., Martínez, M. et al., “Neutropenia febril asociada aquimioterapia en pacientes con neoplasias hematológicasde un centro de referencia en Colombia: característicasclínicas y desenlaces”, Salud Uninorte,2019, 35 (2): 205-220. doi: https://doi.org/10.14482/sun.35.2.616.15.

15. Lobatón, J., González, M., Aruachán, S., Meza, L., García,M., Borré, D. et al., “Caracterización clínico patológicay hallazgos microbiológicos de la neutropenia febrilen pacientes oncohematológicos en una clínica privadaen la ciudad de Montería, Colombia”, Rev Col HematolOncol, 2020, 7 (2): 33-41.

16. Aagaard, T., Reekie, J., Jørgensen, M., Roen, A., Daugaard,G., Specht, L. et al., “Mortality and admission tointensive care units after febrile neutropenia in patientswith cancer”, Cancer Med, 2020, 9 (9): 3033-3042. doi:10.1002/cam4.2955.

17. Hatamabadi, H., Arhami Dolatabadi, A., Akhavan, A. ySafari, S., “Clinical characteristics and associated factorsof mortality in febrile neutropenia patients; a cross sectionalstudy”, Arch Acad Emerg Med, 2019, 7 (1): 39.

18. Guarana, M., Nucci, M. y Nouér, S.A., “Shock and earlydeath in hematologic patients with febrile neutropenia”,Antimicrob Agents Chemother, 2019, 63 (11): e01250-19. doi: 10.1128/AAC.01250-19.